[Comment] Astegolimab and the new era of biologics in COPD care
Chronic obstructive pulmonary disease (COPD) affects 480 million people worldwide and this is projected to increase to nearly 600 million over the next two decades.1 Long-acting beta agonists (LABA) and long-acting muscarinic antagonists (LAMA), often combined with inhaled corticosteroids (ICS), are the cornerstone of
MedScopeGlobal Editorial
May 26, 2026
Shrnutí
Chronic obstructive pulmonary disease (COPD) affects 480 million people worldwide and this is projected to increase to nearly 600 million over the next two decades.1 Long-acting beta agonists (LABA) and long-acting muscarinic antagonists (LAMA), often combined with inhaled corticosteroids (ICS), are the cornerstone of
Klinický význam
Tento článek byl automaticky zpracován ze zdroje The Lancet. Pro plné redakční zpracování nastavte OPENAI_API_KEY.
Zdroj
MedScopeGlobal — ověřte vůči primární literatuře před klinickým použitím.